Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 3.1% – What’s Next?

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) fell 3.1% during trading on Monday . The company traded as low as $0.4687 and last traded at $0.4806. 298,087 shares traded hands during mid-day trading, an increase of 56% from the average daily volume of 191,271 shares. The stock had previously closed at $0.4958.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on CTXR shares. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Citius Pharmaceuticals in a research report on Monday, May 18th. Wall Street Zen lowered Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Zacks Research upgraded Citius Pharmaceuticals to a “hold” rating in a report on Tuesday, May 19th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $5.00.

Citius Pharmaceuticals Trading Up 3.2%

The business’s 50-day simple moving average is $0.58 and its two-hundred day simple moving average is $0.72. The company has a market capitalization of $15.46 million, a PE ratio of -0.26 and a beta of 0.98.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its earnings results on Friday, May 15th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.67). On average, analysts forecast that Citius Pharmaceuticals, Inc. will post -1.87 EPS for the current year.

Institutional Investors Weigh In On Citius Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of CTXR. XTX Topco Ltd bought a new stake in shares of Citius Pharmaceuticals in the second quarter worth $32,000. NewEdge Advisors LLC bought a new position in Citius Pharmaceuticals during the 2nd quarter valued at $40,000. Asset Advisory Group Inc. bought a new position in Citius Pharmaceuticals during the 4th quarter valued at $46,000. Finally, Heights Capital Management Inc. acquired a new position in Citius Pharmaceuticals during the 4th quarter worth $622,000. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.